Display options
Cite
Kim Y, Zheng X, Eschke K, et al. MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination. Cell Mol Immunol. 2022;doi: 10.1038/s41423-021-00814-5.
Kim, Y., Zheng, X., Eschke, K., Chaudhry, M. Z., Bertoglio, F., Tomić, A., Krmpotić, A., Hoffmann, M., Bar-On, Y., Boehme, J., Bruder, D., Ebensen, T., Brunotte, L., Ludwig, S., Messerle, M., Guzman, C., Mandelboim, O., Hust, M., Pöhlmann, S., Jonjić, S., & Čičin-Šain, L. (2022). MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination. Cellular & molecular immunology, . https://doi.org/10.1038/s41423-021-00814-5
Kim, Yeonsu, et al. "MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination." Cellular & molecular immunology vol. (2022). doi: https://doi.org/10.1038/s41423-021-00814-5
Kim Y, Zheng X, Eschke K, Chaudhry MZ, Bertoglio F, Tomić A, Krmpotić A, Hoffmann M, Bar-On Y, Boehme J, Bruder D, Ebensen T, Brunotte L, Ludwig S, Messerle M, Guzman C, Mandelboim O, Hust M, Pöhlmann S, Jonjić S, Čičin-Šain L. MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination. Cell Mol Immunol. 2022 Jan 07; doi: 10.1038/s41423-021-00814-5. Epub 2022 Jan 07. PMID: 34992275; PMCID: PMC8739032.
Copy Download .nbib Format: NLM
Share it on

Cell Mol Immunol. 2022 Jan 07; doi: 10.1038/s41423-021-00814-5. Epub 2022 Jan 07.

MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination.

Cellular & molecular immunology

Yeonsu Kim, Xiaoyan Zheng, Kathrin Eschke, M Zeeshan Chaudhry, Federico Bertoglio, Adriana Tomić, Astrid Krmpotić, Markus Hoffmann, Yotam Bar-On, Julia Boehme, Dunja Bruder, Thomas Ebensen, Linda Brunotte, Stephan Ludwig, Martin Messerle, Carlos Guzman, Ofer Mandelboim, Michael Hust, Stefan Pöhlmann, Stipan Jonjić, Luka Čičin-Šain

Affiliations

  1. Department of Viral Immunology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.
  2. Department of Biotechnology, Institut für Biochemie, Biotechnologie und Bioinformatik, Technischen Universität Braunschweig, Braunschweig, Germany.
  3. Oxford Vaccine Group, University of Oxford, Oxford, UK.
  4. Center for Proteomics, University of Rijeka, Faculty of Medicine, Rijeka, Croatia.
  5. Infection Biology Unit, German Primate Center, Göttingen, Germany.
  6. Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany.
  7. Department of Immunology, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
  8. Infection Immunology, Institute for Medical Microbiology and Hospital Hygiene, Health Campus Immunology, Infectiology and Inflammation, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany; Immune Regulation, Helmholtz Centre for Infection Research, Braunschweig, Germany.
  9. Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
  10. Institute of Virology, Medical University Münster, Münster, Germany.
  11. Institute of Virology, Hannover Medical School (MHH), Hannover, Germany.
  12. Department of Viral Immunology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany. [email protected].
  13. German Centre for Infection Research (DZIF), Hannover-Braunschweig Site, Hannover, Germany. [email protected].
  14. Centre for Individualized Infection medicine (CiiM), a joint venture of HZI and MHH, Hannover, Germany. [email protected].

PMID: 34992275 PMCID: PMC8739032 DOI: 10.1038/s41423-021-00814-5

Abstract

Global pandemics caused by influenza or coronaviruses cause severe disruptions to public health and lead to high morbidity and mortality. There remains a medical need for vaccines against these pathogens. CMV (cytomegalovirus) is a β-herpesvirus that induces uniquely robust immune responses in which remarkably large populations of antigen-specific CD8

© 2021. The Author(s).

Keywords: Cytomegalovirus; Influenza; SARS-CoV-2; Vaccine vector; humoral imunity

References

  1. PLoS One. 2011;6(10):e25858 - PubMed
  2. J Virol. 2001 Mar;75(6):2692-705 - PubMed
  3. Vaccine. 2015 May 5;33(19):2261-2266 - PubMed
  4. PLoS One. 2010 Oct 04;5(10):e13162 - PubMed
  5. Trends Biotechnol. 2011 Sep;29(9):426-34 - PubMed
  6. Sci Rep. 2016 Feb 15;6:21674 - PubMed
  7. PLoS Pathog. 2020 Dec 16;16(12):e1009163 - PubMed
  8. J Virol. 2015 Aug;89(16):8651-6 - PubMed
  9. J Virol. 2010 Aug;84(15):7730-42 - PubMed
  10. Mucosal Immunol. 2017 Mar;10(2):545-554 - PubMed
  11. Cell Host Microbe. 2020 Oct 7;28(4):586-601.e6 - PubMed
  12. Cell. 2020 Apr 16;181(2):271-280.e8 - PubMed
  13. J Virol. 2004 Jul;78(14):7536-44 - PubMed
  14. Clin Vaccine Immunol. 2017 Jan 5;24(1): - PubMed
  15. Virology. 1995 May 10;209(1):236-41 - PubMed
  16. J Immunol. 2017 Sep 1;199(5):1737-1747 - PubMed
  17. Clin Infect Dis. 2012 Jul;55(1):19-25 - PubMed
  18. PLoS Negl Trop Dis. 2011 Aug;5(8):e1275 - PubMed
  19. J Immunol. 2006 Jul 1;177(1):450-8 - PubMed
  20. Methods Mol Biol. 2021;2244:133-158 - PubMed
  21. Mol Cell. 2020 May 21;78(4):779-784.e5 - PubMed
  22. Nat Med. 2009 Mar;15(3):293-9 - PubMed
  23. Nature. 2011 May 26;473(7348):523-7 - PubMed
  24. PLoS Pathog. 2019 Sep 30;15(9):e1008043 - PubMed
  25. Nature. 2020 Oct;586(7830):594-599 - PubMed
  26. J Virol. 2004 Mar;78(5):2255-64 - PubMed
  27. Cell Rep. 2020 Oct 13;33(2):108254 - PubMed
  28. J Virol. 2007 Dec;81(24):13825-34 - PubMed
  29. PLoS One. 2019 Jul 22;14(7):e0220196 - PubMed
  30. Vaccine. 2017 Jun 27;35(30):3780-3788 - PubMed
  31. Vaccine. 2010 Dec 16;29(2):266-73 - PubMed
  32. PLoS Pathog. 2016 Dec 15;12(12):e1006072 - PubMed
  33. J Immunol. 2003 Feb 15;170(4):2022-9 - PubMed
  34. J Virol. 1998 Nov;72(11):9404-6 - PubMed
  35. PLoS One. 2010 Mar 12;5(3):e9681 - PubMed
  36. J Virol. 2016 Apr 14;90(9):4402-4411 - PubMed
  37. Nat Commun. 2021 Mar 11;12(1):1577 - PubMed
  38. J Virol. 2011 Oct;85(19):10346-53 - PubMed
  39. J Immunother. 2012 Jun;35(5):390-9 - PubMed
  40. J Immunol. 2011 Aug 15;187(4):1722-32 - PubMed
  41. J Exp Med. 2005 Sep 5;202(5):673-85 - PubMed
  42. PLoS Pathog. 2014 Feb 20;10(2):e1003962 - PubMed
  43. Virology. 2011 Mar 30;412(1):36-45 - PubMed
  44. Front Immunol. 2018 May 07;9:991 - PubMed
  45. J Virol. 2019 Jan 4;93(2): - PubMed
  46. Lancet Infect Dis. 2020 Jul;20(7):827-838 - PubMed
  47. J Clin Invest. 2010 Dec;120(12):4532-45 - PubMed
  48. Sci Transl Med. 2019 Jul 17;11(501): - PubMed
  49. Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16550-5 - PubMed
  50. PLoS Pathog. 2019 Sep 16;15(9):e1008036 - PubMed
  51. Nature. 2020 Oct;586(7830):516-527 - PubMed
  52. Front Immunol. 2011 Dec 28;2:85 - PubMed
  53. Vaccines (Basel). 2019 Oct 17;7(4): - PubMed
  54. J Immunol Methods. 1980;36(1):77-80 - PubMed
  55. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(6):226-49 - PubMed
  56. J Virol. 2002 Jan;76(1):151-64 - PubMed
  57. Immunity. 2010 Oct 29;33(4):492-503 - PubMed
  58. J Virol. 2000 Dec;74(24):11495-503 - PubMed
  59. Vaccines (Basel). 2014 Jul 29;2(3):624-41 - PubMed
  60. Med Microbiol Immunol. 2012 Nov;201(4):551-66 - PubMed
  61. MMWR Morb Mortal Wkly Rep. 2020 Feb 21;69(7):177-182 - PubMed
  62. BMJ. 2020 Dec 2;371:m4714 - PubMed
  63. Ann Rheum Dis. 2011 Feb;70(2):373-9 - PubMed

Publication Types

Grant support